Product Description
Aprotinin is a single chain polypeptide isolated from bovine lung with antifibrinolytic and anti-inflammatory activities. As a broad-spectrum serine protease inhibitor, aprotinin bovine competitively and reversibly inhibits the activity of a number of different esterases and proteases, including trypsin, chymotrypsin, kallikrein, plasmin, tissue plasminogen activator, and tissue and leukocytic proteinases, resulting in attenuation of the systemic inflammatory response (SIR), fibrinolysis, and thrombin generation. This agent also inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Aprotinin)
Mechanisms of Action: SP Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|